Trial Profile
An open label study to assess the efficacy, safety and tolerability of Cozaar plus (losartan potassium 50mg/hydrochlorothiazide 12.5mg) possibly titrated up to Cozaar plus-F (losartan potassium 100mg/hydrochlorothiazide 25mg) in patients with essential hypertension
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Losartan/hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Organon
- 18 May 2007 New trial record.